

28. The vaccine of claim **24**, wherein the vaccine has a protein content, and the protein content is greater than 95% recombinant *P. falciparum* CSP as measured by gel densitometry.

29. The vaccine of claim **28**, wherein the protein content is at least about 99% recombinant *P. falciparum* CSP as measured by gel densitometry.

30. A method of eliciting an immune response against malaria in an animal or human comprising administering the vaccine of claim **24** to the animal or human.

31. A method of immunizing an animal or human against malaria, comprising administering to the animal or human the vaccine of claim **24**.

32. The method of claim **30**, wherein the vaccine is administered intramuscularly.

33. A process of producing a soluble recombinant *P. falciparum* CSP, comprising the steps of:

providing *E. coli* cells containing a nucleotide sequence that expresses a recombinant *P. falciparum* CSP according to claim **1**;

inducing expression of the recombinant *P. falciparum* CSP in the *E. coli* cells;

lysing the *E. coli* cells to produce *E. coli* lysate;

purifying the recombinant *P. falciparum* CSP from the supernatant of the *E. coli* lysate without denaturing and refolding the recombinant *P. falciparum* CSP.

34. The process of claim **33**, wherein the *E. coli* is cultured in media substantially free of components derived from animals.

35. The process of claim **34**, wherein the media comprises a combination of ingredients including Phytone, yeast

extract, ammonium sulfate, potassium phosphate monobasic, sodium phosphate dibasic, MgSO₄, glycerol, dextrose and kanamycin.

36. The process of claim **33**, wherein the recombinant *P. falciparum* CSP comprises one or more histidine tags at one or both ends, and wherein the purification step consists essentially of:

purifying the soluble protein over a nickel affinity column; and

purifying the soluble protein over a Q-sepharose anion exchange column and recovering a purified protein, wherein the purification step does not include any other chromatographic separation.

37. The process of claim **33**, further comprising the step of filtering the purified protein.

38. The process of claim **33**, wherein the purified protein is at least about 90% pure recombinant *P. falciparum* CSP as measured by gel densitometry.

39. The process of claim **38**, wherein the purified protein is at least about 95% pure recombinant *P. falciparum* CSP as measured by gel densitometry.

40. The process of claim **33**, the purified protein comprises less than 1 ng/ml of *E. coli* host proteins.

41. The process of claim **33**, wherein the purified protein comprises less than about 5 endotoxin units per microgram protein.

42. The process of claim **33**, wherein the *E. coli* cell is SHUFFLE™ strain.

43. A vaccine comprising the soluble protein produced by the process of claim **33**.

* * * * *